The company, which focuses developing krill oil-based forms of omega-3 phospholipid therapies for treating and preventing cardiometabolic disorders, said it completed the Phase II, double-blind, placebo-controlled TRIFECTA study and the Pharmacokinetic PK trial. These results would be crucial in Acasti's talks with the FDA on approval to conduct a Phase III trial in the U.S.
"The conclusion of the clinical studies is a key milestone in our drug development program and we look forward to obtaining results for the two trials," said Acasti interim president and CEO Andre Godin in a statement.
Must Read: Warren Buffett's 25 Favorite Stocks
The stock was up 10.55% to $1.11 at 11:39 a.m. More than 3.2 million shares had changed hands, compared to the average volume of 414,126.
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.